alexa Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors
ISSN: 2167-1095

Journal of Hypertension: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO2

Rutahoile WM1, David NM1, Angela AP1, Abdallah ZH1, Xiao Li Zhou2, Huang Wei1 and Lei Han1*

1The First Affiliated Hospital of Chongqing Medical University, China

2Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, China

*Corresponding Author:
Lei Han
Chongqing Medical University
1 Youyi Road, Yuzhong District
Chongqing, 400016, P. R. China
Tel: 008618323855745
E-mail: [email protected]

Received Date: January 27, 2017; Accepted Date: February 06, 2017; Published Date: February 13, 2017

Citation: Rutahoile WM, David NM, Angela AP, Abdallah ZH, Zhou XL, et al. (2017) Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO2. J Hypertens 6: 237. doi:10.4172/2167-1095.1000237

Copyright: © 2017 Rutahoile WM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.

 

Abstract

Background: In settings where new drugs for pulmonary arterial hypertension (PAH) are not possible due to lack of availability and cost; PDE-5 inhibitors such as sildenafil is the drug of choice in the management of PAH. In this study we performed a meta-analysis to evaluate the effects of oral sildenafil in PAH, pointing on peak VO2 improvement. Methods: We retrieved randomized controlled trials (RCTs) of the effects of PDE-5 inhibitors, sildenafil in patients with PAH using PubMed, Medline, Embase, Cochrane Library, Google scholar and manual search from 2011 to 2016. Random controlled trials that compared oral sildenafil with placebo were selected. Data for populations, interventions, and outcomes were extracted independently by 2 investigators, and disagreements were resolved by consensus. Quality assessment was performed using the Cochrane risk-of-bias tool. Results: Four randomized controlled clinical trials including a total of three hundred thirty six patients were identified in the primary analysis, with 51.5% patients in the PDE-5 inhibitors treatment group and 48.5% patients in the placebo group. Two studies show reduction in statistical significance of mPAP (MD -4.15, 95% CI -17.28 to 8.98; P<0.00001) and PVR (MD -51.27, 95% CI -127.63 to 25.10; P<0.00001. Other three studies shown statistical significance in reduction of mPCWP (MD -2.70, 95% CI -7.14 to 1.75; P<0.0003). Other two studies which accessed the quality of life show no much differences among the two groups (MD 1.18, 95% CI -4.92 to 7.27; P<0.00001). However, all four trials, shown no statistical significant improvement in peak VO2, of patients allocated to PDE-5 inhibitors group, sildenafil compared to the placebo group with heterogeneity (MD 0.61, 95% CI -0.37 to 1.59, P=0.21, I2=34%). Conclusion: The results of present review suggest that treatment with PDE-5 inhibitors; sildenafil reduced mPAP, PVR and mPCWP but could not significantly improve the peak VO2.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords